5th Lipid Nanoparticles (LNP) Development Summit Europe

5th Lipid Nanoparticles (LNP) Development Summit Europe is organized by Hanson Wade and will be held from Sep 23 - 24, 2026 at Dorint Kurfürstendamm Berlin, Berlin, Germany.

Description:
Spearheading End-to-End LNP Development by Leveraging Novel Lipids, Incorporating Automation & Improving Reliability of LNP Analytics to Accelerate LNPs from Research to Market

The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin at a pivotal moment for the field, as LNPs move beyond COVID-19 vaccines into broader therapeutic applications, including gene editing, oncology and in vivo cell therapy. This meeting brings together leading biotech, pharma and academic experts to tackle the biggest barriers preventing LNPs from reaching their full clinical potential.

What sets this event apart is its end-to-end focus, covering everything from early design and intracellular delivery, through analytical and CMC strategy, to regulatory alignment and scalable manufacturing. Unlike traditional meetings, it goes beyond well-known challenges to spotlight next-generation innovations, including extrahepatic targeting, hybrid nanoparticle systems and strategies for repeat dosing and reduced toxicity.

The timing couldn’t be more critical. As the industry faces increasing scrutiny around safety, delivery precision and commercial viability, there is a growing need to align innovation with real-world application and regulatory expectations. This summit provides a unique platform to do exactly that, through expert-led sessions, interactive debates and practical case studies.